[@b4-ehp-118-a468a] reported an association between polybrominated diphenyl ether (PBDE) levels in cord blood and neurodevelopmental effects in the children at specific ages. As a basis for their work, the authors cited several animal studies that reported causal relationships between prenatal exposure to PBDEs and developmental neurotoxicity. We are concerned that Herbstman et al.'s research suffers from investigator bias based on the reasons that follow.

First, the U.S. Environmental Protection Agency (EPA) cosponsored an expert panel that refuted the experimental design employed in most of the studies cited by [@b4-ehp-118-a468a] as a basis for their work. The U.S. EPA expert panel concluded that the experimental design failed to control for litter effects ([@b5-ehp-118-a468a]).

Next, the potential for specific brominated flame retardants to cause developmental neurotoxicity has been evaluated under Good Laboratory Practice (GLP) standards and according to validated test guidelines. In each case, the claims of developmental neurotoxicity from non-GLP, non-guideline studies were not reproducible (reviewed by [@b10-ehp-118-a468a]). This is significant because in Europe, data generated from studies performed under GLP and according to validated test guidelines are considered the highest quality and most reliable ([@b2-ehp-118-a468a]). Further, regulatory agencies in Europe and the United States seem to have shifted their stance on the non-GLP, non-guideline studies that have reported brominated flame retardant--induced developmental neurotoxicity. For example, when the European Union issued their Risk Assessment Report on hexabromocyclododecane (HBCD), a brominated flame retardant ([@b3-ehp-118-a468a]), they stated that

> ... [@b1-ehp-118-a468a] \[i.e., the study reporting HBCD-induced developmental neurotoxicity\] is not performed according to current guideline and GLP .... However, similar results on developmental neurotoxicity have been published for decabromodiphenylether by the same authors using the same method \[e.g., [@b9-ehp-118-a468a], which was cited by [@b4-ehp-118-a468a]\]. For decabromodiphenylether it has been agreed to perform a new toxicokinetics/developmental neurotoxicity study according to a modified OECD guideline and GLP. The results from this new decabromodiphenylether study will serve as guidance on how to interpret the data from the Eriksson study, and may also serve as a basis on how to proceed with further testing of neurotoxicity.

For two of the studies cited by [@b4-ehp-118-a468a], which were used by the U.S. EPA for deriving reference doses for PBDEs 153 and 209 ([@b6-ehp-118-a468a], [@b7-ehp-118-a468a]), the U.S. EPA was unable to obtain the raw data. However, when the raw data were obtained for the PBDE 209 study (i.e., [@b9-ehp-118-a468a]) by a third party, who subsequently provided the data to the U.S. EPA, the agency acknowledged that the data were not suitable for use with human health assessment ([@b8-ehp-118-a468a]).

We mention the above information because [@b4-ehp-118-a468a] cited only animal studies that reported PBDE-induced developmental neurotoxicity as support for their work. Although the authors discussed one epidemiological study that reported findings inconsistent with their own, [@b4-ehp-118-a468a] reverted back to the positive animal studies as support for their work. They did not discuss or cite any animal studies that reported contradictory findings. This is significant because it may have introduced a formidable source of bias when [@b4-ehp-118-a468a] were interpreting their results. The exclusion may also mislead the readership of *EHP*.

[^1]: M.B. has received a total of US\$2,000 from the brominated flame retardant industry for his contribution to three publications in 2008--2009, but he received no form of remuneration for his work on this letter.
